Full-Time
Sr. Materials Engineer
Confirmed live in the last 24 hours
Medtronic
10,001+ employees
Develops and manufactures medical devices and therapies
Compensation Overview
$109.1k - $152.4kAnnually
Senior
Peabody, MA, USA
Position works a hybrid model and will be onsite in Danvers, MA – 4 days per week.
You match the following Medtronic's candidate preferences
Employers are more likely to interview you if you match these preferences:
- Master’s degree in Plastics Engineering or related engineering field
- Two (2) years of experience as materials engineer or related occupation in plastics, process or manufacturing engineering
- At least two (2) years’ experience with Extrusion & molding process and project engineering
- At least two (2) years’ experience with Process & Tooling development & Validation including IQ, OQ, PQ
- At least two (2) years’ experience with Supporting/troubleshooting daily process and yield improvement
- At least two (2) years’ experience with DOE & SPC
- At least two (2) years’ experience with Authoring validation & risk assessment documents and work instructions
- At least two (2) years’ experience with Root cause analysis and CAPA
- At least two (2) years’ experience with Polymer resins and tooling maintenance
- At least two (2) years’ experience with Good Manufacturing Practices (GMP)
- Perform process design, development, and materials selection to support new and improved extruded catheter sub-assemblies
- Perform and maintain polymer rheological characterization program to shorten materials selection process benchmark melt properties
- Work with multi-layer Extrusion or Injection Molding process & coordinate multiple projects simultaneously
- Leverage Installation qualification (IQ), Operational qualification (OQ), Performance qualification (PQ) to develop new process while authoring validation reports
- Provide daily production troubleshooting & yield improvement
- Apply Design of Experiment (DOE) & Statistical Process Control (SPC) tools to optimize process
- Leverage root cause investigation as part of problem solving, CAPA (Corrective and Preventive Action)
- Develop tooling maintenance plan and overseeing tool readiness
- Implement and follow Good Manufacturing Practices (GMP)
Medtronic provides medical technology, services, and solutions to improve patient care. The company develops a variety of medical devices, including pacemakers, insulin pumps, surgical tools, and neurostimulation devices, which help diagnose, prevent, and treat chronic diseases. These products are used by hospitals and healthcare professionals around the world. Medtronic stands out from competitors by not only focusing on product development but also offering training, patient management programs, and technical support to healthcare providers. The goal of Medtronic is to enhance patient outcomes and lower healthcare costs through comprehensive solutions.
Company Size
10,001+
Company Stage
IPO
Total Funding
$3.2M
Headquarters
Fridley, Minnesota
Founded
1949
Simplify's Take
What believers are saying
- Growing demand for connected medical devices boosts Medtronic's digital health solutions.
- Personalized medicine trend aligns with Medtronic's tailored therapies like BrainSense™ Adaptive DBS.
- Chronic disease prevalence ensures stable market for Medtronic's insulin pumps and pacemakers.
What critics are saying
- Increased competition in renal denervation may impact Medtronic's market share.
- Potential CMS delays could hinder U.S. market expansion for Symplicity™ Spyral system.
- New CFO appointment may lead to strategic shifts affecting operations.
What makes Medtronic unique
- Medtronic leads in personalized medicine with BrainSense™ Adaptive DBS system.
- The company excels in minimally invasive surgical tools and technologies.
- Medtronic integrates AI in medical devices for enhanced diagnostics and treatment.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Employee Assistance Program
Wellness Program
Company News
GALWAY, Ireland, Feb. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2025 on Tuesday, February 18, 2025. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's third quarter of fiscal year 2025, which ended on Friday, January 24, 2025. Medtronic will host a video webcast at 7:00 a.m
GALWAY, Ireland, Jan. 21, 2025 /PRNewswire/ - Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Thierry Piéton has been appointed Chief Financial Officer for the company, effective March 3, 2025.
Medtronic's heart rhythm management portfolio, including its insertable cardiac monitors (ICMs) and pulsed field ablation (PFA) systems, have had a significant footprint at AF Symposium 2025, a three-day conference in Boston focused on advanced atrial fibrillation (AFib) technologies.
Recall that Medtronic acquired the renal denervation technology from Mountain View, California-based Ardian back in 2010 for $800 million plus milestone payments.
Medtronic Receives CE Mark for BrainSense™ Adaptive Deep Brain Stimulation, Optimizing Parkinson’s Disease Treatment in Europe. by Jasmine Pennic 01/14/2025 Leave a Comment. What You Should Know: – Medtronic (NYSE:MDT), a global leader in healthcare technology, announced it has received CE Mark approval for its groundbreaking BrainSense™ Adaptive deep brain stimulation (aDBS) technology in the European Union and the United Kingdom. – The CE approval marks a significant advancement in personalized Parkinson’s disease treatment, offering patients in Europe access to a more responsive and tailored therapy.BrainSense™ aDBS: A New Era of Personalized Parkinson’s TreatmentFor three decades, deep brain stimulation (DBS) has been a valuable tool for managing Parkinson’s disease symptoms. This technology involves implanting a device that sends electrical signals to specific brain regions to disrupt abnormal nerve signals that cause tremors and other movement difficulties.BrainSense™ aDBS takes this therapy to a new level by dynamically adjusting stimulation based on each patient’s unique brain activity. This personalized approach allows for more precise and effective treatment, potentially improving motor control and quality of life for individuals with Parkinson’s disease.Clinical Validation and ResearchThe ADAPT-PD trial, the largest and longest assessment of aDBS to date, has demonstrated the clinical benefits of this technology. The study, conducted in both clinical and home settings, evaluated the safety and effectiveness of aDBS compared to conventional continuous DBS.Expanding Access to Innovative TherapiesMedtronic’s BrainSense™ aDBS technology is expected to be available in Europe in early 2025
National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure. Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical programGALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. This national coverage analysis was initiated by CMS in response to Medtronic's request to support Medicare beneficiary access to the Symplicity™ Spyral renal denervation (RDN) system, used in the Symplicity blood pressure procedure. "Hypertension is a global health epidemic that impacts a wide variety of patients," said Jason Weidman, senior vice president and president of the Coronary and Renal Denervation business within the Cardiovascular Portfolio at Medtronic. "As the leader in developing a minimally invasive treatment option for hypertension, Medtronic has been closely engaged with CMS to establish a national coverage pathway for Symplicity Spyral
Medtronic announced today that it has entered into an exclusive US distribution agreement with Contego Medical.
European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease. GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center. This landmark approval and first-in-Europe patient programming demonstrate significant advancements in personalized DBS therapy for people with Parkinson's in Europe, including the UK. For 30 years, people with Parkinson's disease have benefitted from deep brain stimulation (DBS), a technology that transmits electric signals to the brain to disrupt certain unwanted movement
Medtronic has formed an exclusive five-year MagnetOs sales agency agreement with Kuros.
Irish medtech company Fire1 has raised $120 million in new financing. Led by Conor Hanley, Fire1 aims to revolutionize heart failure management with an innovative remote sensor.
GALWAY, Ireland, Jan. 6, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 43rd annual J.P. Morgan healthcare conference on Monday, January 13, 2025. Geoff Martha, Medtronic chairman and chief executive officer, will make a formal presentation and answer questions on the company beginning at 2:15 p.m. PST (4:15 p.m. CST)
Medtronic plc (NYSE:MDT), the global healthcare technology leader based in Galway, Ireland, has announced its participation in the 43rd annual J.P. Morgan healthcare conference on Monday, January 13, 2025.